Literature DB >> 20732435

Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

Nishitha Reddy1, Katayoun Rezvani, A John Barrett, Bipin N Savani.   

Abstract

Epstein-Barr virus (EBV)-associated postallogeneic stem cell transplantation (SCT) lymphoproliferative disorder (PTLD) is often life threatening. The risk of EBV reactivation is highest in older patients, T cell-depleted SCT (in vivo or vitro), and in unrelated or mismatched SCT. Cumulative numbers of patients with EBV reactivation and PTLD are rising as more patients at high risk for EBV reactivation and PTLD are receiving allo-SCT. Novel but easily applicable strategies are needed to prevent EBV reactivation and PTLD to serve the needs of the increasingly enlarging population of high-risk SCT recipients across the globe. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20732435      PMCID： PMC3763478          DOI： 10.1016/j.bbmt.2010.08.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  76 in total

1.  Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

Authors:  J W van Esser; B van der Holt; E Meijer; H G Niesters; R Trenschel; S F Thijsen; A M van Loon; F Frassoni; A Bacigalupo; U W Schaefer; A D Osterhaus; J W Gratama; B Löwenberg; L F Verdonck; J J Cornelissen
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

Review 2.  Extending cord blood transplant to adults: dealing with problems and results overall.

Authors:  Claudio G Brunstein; Mary J Laughlin
Journal:  Semin Hematol       Date:  2010-01       Impact factor: 3.851

Review 3.  Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation.

Authors:  Hans-Joachim Wagner; Cliona M Rooney; Helen E Heslop
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

Review 4.  Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient.

Authors:  M A Lones; I Kirov; J W Said; I P Shintaku; S Neudorf
Journal:  Bone Marrow Transplant       Date:  2000-11       Impact factor: 5.483

5.  Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients.

Authors:  J N Barker; P L Martin; J E Coad; T DeFor; M E Trigg; J Kurtzberg; D J Weisdorf; J Wagner
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

6.  CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.

Authors:  I Kuehnle; M H Huls; Z Liu; M Semmelmann; R A Krance; M K Brenner; C M Rooney; H E Heslop
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

7.  The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.

Authors:  M Majewski; M Korecka; P Kossev; S Li; J Goldman; J Moore; L E Silberstein; P C Nowell; W Schuler; L M Shaw; M A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

8.  Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique.

Authors:  E Meijer; I C M Slaper-Cortenbach; S F T Thijsen; A W Dekker; L F Verdonck
Journal:  Bone Marrow Transplant       Date:  2002-02       Impact factor: 5.483

9.  Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection.

Authors:  Andrew D Hislop; Nicola E Annels; Nancy H Gudgeon; Alison M Leese; Alan B Rickinson
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

10.  Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.

Authors:  C Münz; K L Bickham; M Subklewe; M L Tsang; A Chahroudi; M G Kurilla; D Zhang; M O'Donnell; R M Steinman
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307
View more
  25 in total

1.  Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies.

Authors:  Wichai Chinratanalab; Nishitha Reddy; John P Greer; David Morgan; Brian Engelhardt; Adetola Kassim; Stephen J Brandt; Madan Jagasia; Stacey Goodman; Bipin N Savani
Journal:  Exp Hematol       Date:  2012-01-21       Impact factor: 3.084

2.  Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study.

Authors:  M Wu; J Sun; Y Zhang; F Huang; H Zhou; Z Fan; L Xuan; G Yu; X Guo; M Dai; R Feng; Q Liu
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

Review 3.  Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.

Authors:  Nishitha Reddy; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-11       Impact factor: 5.742

4.  A 47-year-old stem cell transplant recipient with fever, cough and chest pain.

Authors:  Omar S Salh; Omar N Nadhem; Sanket R Thakore; Ruba A Halloush; Faisal A Khasawneh
Journal:  Can Respir J       Date:  2015 May-Jun       Impact factor: 2.409

5.  Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.

Authors:  I García-Cadenas; N Castillo; R Martino; P Barba; A Esquirol; S Novelli; G Orti; A Garrido; S Saavedra; C Moreno; M Granell; J Briones; S Brunet; F Navarro; I Ruiz; N Rabella; D Valcárcel; J Sierra
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

6.  Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time.

Authors:  R Parody; R Martino; R de la Cámara; A García-Noblejas; A Esquirol; I Garcia-Cadenas; T Villaescusa; D Caballero; M Rovira; F Fernandez-Avilés; F J Marquez-Malaver; I Espigado; C Castilla-Llorente; I Heras; M A Cabero; J R Cabrera; P Barba; D Valcarcel; I Sánchez-Ortega; R F Duarte; D Serrano; F Carretero; L Vazquez
Journal:  Bone Marrow Transplant       Date:  2014-10-27       Impact factor: 5.483

7.  Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder.

Authors:  Hiroaki Shimizu; Takayuki Saitoh; Hiroko Koya; Akinori Yuzuriha; Takumi Hoshino; Nahoko Hatsumi; Satoru Takada; Tomohito Nagaki; Yoshihisa Nojima; Toru Sakura
Journal:  Int J Hematol       Date:  2011-10-29       Impact factor: 2.490

8.  Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT.

Authors:  Courtney D Fitzhugh; Matthew M Hsieh; Tiffani Taylor; Wynona Coles; Katherine Roskom; Delon Wilson; Elizabeth Wright; Neal Jeffries; Christopher J Gamper; Jonathan Powell; Leo Luznik; John F Tisdale
Journal:  Blood Adv       Date:  2017-04-19

9.  Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.

Authors:  Minhtran Charlotte Ngo; Jun Ando; Ann M Leen; Sravya Ennamuri; Natalia Lapteva; Juan F Vera; Amelia Min-Venditti; Martha P Mims; Helen E Heslop; Catherine M Bollard; Stephen Gottschalk; Cliona M Rooney
Journal:  J Immunother       Date:  2014-05       Impact factor: 4.456

10.  ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation.

Authors:  Joseph Pidala; Marcie Tomblyn; Taiga Nishihori; Ernesto Ayala; Teresa Field; Hugo Fernandez; Lia Perez; Fred Locke; Melissa Alsina; Jose Leonel Ochoa; Janelle Perkins; Cheryl Tate; Jamie Shapiro; Michelle Conwell; Ryan Bookout; Claudio Anasetti
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-06       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.